Cooley advised Reata Pharmaceuticals on a $275 million debt financing from funds managed by Pharmakon Advisors, and on an amendment and restatement of its development and commercialization funding agreement with affiliates of Blackstone Life Sciences. Reata – a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases –trades on the Nasdaq Global Market under the symbol RETA. Lawyers Michael Tollini, Mischi a Marca, Addison Pierce, Kelsey Watkins and Xueqing Li led the Cooley team.